KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Preferred Stock Liabilities (2020 - 2021)

Recursion Pharmaceuticals (RXRX) has disclosed Preferred Stock Liabilities for 2 consecutive years, with $448.3 million as the latest value for Q1 2021.

  • For the quarter ending Q1 2021, Preferred Stock Liabilities rose 122.92% year-over-year to $448.3 million, compared with a TTM value of $448.3 million through Mar 2021, up 122.92%, and an annual FY2020 reading of $448.3 million, up 122.92% over the prior year.
  • Preferred Stock Liabilities was $448.3 million for Q1 2021 at Recursion Pharmaceuticals, roughly flat from $448.3 million in the prior quarter.
  • Across five years, Preferred Stock Liabilities topped out at $448.3 million in Q4 2020 and bottomed at $201.1 million in Q1 2020.